RU-486: the abortion pill by de Costa, Caroline
Caroline de Costa
The Abortion Pill
First published in 2007  by Boolarong Press
Copyright      ©      Caroline de Costa
This book is copyright. Apart from any fair dealing for the purpose of private 
study, research, criticism or review, as permitted under the Copyright Act, 
no part may be reproduced by any process without written permission. 
Inquiries should be addressed to the Publishers.
All rights reserved.
de Costa Caroline, 1947 - .
RU 486.
ISBN 9781921054334 (pbk).
1. Mifepristone - Australia. 2. Mifepristone - Government
policy - Australia. 3. Abortifacients - Australia. I.
615.766
BOOLARONG PRESS
1/655 Toohey Road, Salisbury 4107
Typeset by Watson Ferguson & Company
Printed and Bound by Watson Ferguson & Company
ACKNOWLEDGEMENTS
Many people have contributed to my knowledge of medical 
abortion and thus to the preparation of this book: Dr Mike Carrette, 
Dr Darren Russell, Naomi de Costa, Senator Jan McLucas and her 
staff, Senator Claire Moore and her staff, Senator Lyn Allison and 
her staff, Dr Sharman Stone and her staff, Dr Lesley Clark, the staff 
of Cairns Base Hospital Library, Cait Calcutt, Dr Leslie Cannold, 
Professor David Healy, Dr Sally Cockburn, Dr Michele Moore, 
Dr Margaret Sparrow, Dr Carol Shand and Dr Andre Ulmann. I 
also acknowledge the contributions made to the campaign to bring 
RU486 to Australia by so many women – and men – who for reasons 
of space I have been unable to name.
i
LIST OF COMMON ABBREVIATIONS 
USED IN THIS BOOK
ACOG – American College of Obstetricians and Gynecologists
AMA – Australian Medical Association (also American Medical 
Association, abbreviation not used in this book)
FDA – Food and Drug Administration (United States)
FIGO – International Federation of Obstetricians and 
Gynaecologists
MIMS - Monthly Index of Medical Supplies
MJA – Medical Journal of Australia
NHS – National Health Service (United Kingdom)
PC – Population Council
RANZCOG – Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists
RCOG – Royal College of Obstetricians and Gynaecologists
TGA – Therapeutic Goods Administration
WHO – World Health Organisation
ii
CONTENTS
      Acknowledgements                            i  
      List of common abbreviations used in this book              ii  
  1. Introduction                             1
  2. Some basic facts about RU 486                                          6
  3. Who has abortions in Australia, 
    and what services are currently available for them?          10
  4. The ‘abortion pill’ and the ‘morning-after pill’ – 
      what’s the difference?                                                        22
  5. The history of RU486 in Europe 
      and the United States                                                        25
  6. The many uses of misoprostol                                          37
  7. Alternatives to mifepristone for medical abortion       46
  8. Other medical uses of mifepristone                              51
  9. The side effects, risks and complications
      of medical abortion                                                     55
10. The New Zealand experience with RU486                   62
11. Recent experience with mifepristone in 
      North America, Europe, Asia and elsewhere                   68
12. Medical abortion and Australian law                              75
13. Early Australian attempts to introduce 
   medical abortion – and the opposition                            85
14. The Harradine Amendment
      and the decade 1996-2006                                         89
15. 2005 – the debate surrounding the 
      Harradine Admendment                                                   96
16. The Senate Inquiry into the Private Members’ Bill 107
17. The reversal of the Harradine Amendment 111
18. The current situation – and the future 122
      References 128
      An A-Z of abortion 134
      References A-Z 169
      Index 170
INTRODUCTION 
On a bright winter’s day at the beginning of July, 2006, I walked 
from my office in the JCU School of Medicine in Cairns and 
across the three city blocks to the rooms of my colleague Dr Mike 
Carrette. Waiting for me with Mike was a woman I will call Joanne. 
I had met Joanne the previous week when I had shared a three way 
consultation with herself and Mike.
Joanne was 43 years old and had recently discovered that she was 
six weeks pregnant. The pregnancy was unplanned. In a previous 
pregnancy Joanne had suffered an episode of thrombo-embolism 
– a blood clot had formed in her leg and migrated to her lungs. 
Fortunately this life-threatening condition had not been fatal for her, 
although she required anti-coagulant medication for the ensuing six 
months. The physician caring for her at the time had also given her 
some strongly worded advice – she should avoid further pregnancy, 
which posed a serious threat to her life. 
In addition to her medical problems Joanne, as a divorced single 
mother, felt quite unable to proceed with another pregnancy at 
her age. She had consulted her general practitioner, who talked 
sympathetically with her about all her options.  After thinking long 
and hard, Joanne decided that she should undergo an abortion. She 
was also interested in the possibility of a medical abortion, in order 
to avoid an anaesthetic.
At her first consultation with Mike and myself, the procedure 
of induced medical abortion using the drugs mifepristone (RU486) 
and misoprostol was explained. Joanne brought with her a friend, 
Doreen, to act as support person throughout the process, which 
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would take place in Joanne’s home. Exactly what Joanne could 
expect to feel, the various risks that were involved, and what she 
should do in any kind of emergency, were all outlined. She was 
supplied with written information about the world-wide experience 
of medical abortion and a detailed consent form to take home and 
read. The appointment for the following week was pencilled in.
We met again as planned. Joanne was quite sure of her decision 
and had brought with her the signed consent form. Mike unwrapped 
the package of mifepristone and as we both watched Joanne took a 
sip of water and swallowed it down. Would she feel any side effects 
that afternoon? she asked. Not likely, we replied, RU486 itself has 
few side effects. But she had contact numbers for both of us in case 
of any problems.
Two days later we met for the third time. On this occasion Joanne 
had four tablets of the drug misoprostol inserted vaginally. She had 
already been given prescriptions for antibiotics and painkillers. 
She was driven home by Doreen who stayed in close touch with 
us by phone. Two hours later Doreen reported that Joanne was 
experiencing some contractions and bleeding; within half an hour 
the abortion process was complete and bleeding and pain were 
settling.
Joanne had just become the first woman in twelve years to 
undergo a legal abortion  using RU486 in Australia, and one of the 
very few ever to use the drug in this country. 
Why is this event in any way remarkable? RU486, as mifepristone1  
continues to be more widely known, has been available in France 
and Switzerland since 1988, the United Kingdom since 1991, 
most other European countries since the early-mid 90s, and the 
United States since 2000. It is used legally in Russia, India, China, 
Israel, Turkey, Tunisia and New Zealand, amongst many other 
countries. In almost all these places its use evokes little in the way 
of controversy. Its actions, side effects and potential risks have been 
widely studied, and the evidence shows that it is safe, effective, 
1 Throughout this book the names RU 486 and mifepristone will be used 
interchangeably – they are the same thing.
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and highly acceptable to women, both for early abortion – usually 
implying up to nine weeks of pregnancy – and for the much less 
common procedure of late abortion. However in Australia the drug, 
after initial (promising) trials directed by Professor David Healy 
of Monash University, became the focus for political manoeuvring 
that had nothing to do with the health or human rights of Australian 
women. Under an extraordinary piece of legislation known as the 
Harradine Amendment, the use or import of the drug was prohibited 
without the personal permission of the Federal Minister of Health. 
This had the effect of discouraging pharmaceutical companies from 
applying to the Australian Therapeutic Goods Administration 
(TGA) for approval to import and market the drug – which is the 
normal pathway by which drugs developed and manufactured 
overseas enter the country. It also meant that Australian women 
have been poorly informed about something quite familiar to their 
sisters in Europe, North America and elsewhere, and denied a 
choice that is widely available in so many other countries.
This situation was partly remedied by the overturning of the 
Harradine Amendment by a conscience vote in both Houses of 
Parliament in February 2006. This unique event occurred because 
a cross-party group of women senators introduced a Private 
Members’ Bill in the Senate, which was passed in that House and 
a week later in the Lower House, the House of Representatives. 
The bringing of this piece of legislation to the Parliament, and the 
events that preceded it, demonstrated an extraordinary unity of 
purpose between women from all shades of the political spectrum 
and from a huge range of different backgrounds.  There was clear 
recognition from these women- and of course from many men – 
that access to safe, legal abortion must be a fundamental right of 
Australian women and that this is the opinion of a majority of the 
population. Allowing access to RU486 extends that right, increasing 
the choices available to women having to make the difficult decision 
about terminating an unwanted pregnancy. Widespread availability 
of RU486 in this country also offers the possibility of improving 
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access of some Australian  women to abortion, particularly rural 
women and women from certain ethnic groups.
However the overturning of the Harradine legislation did not 
immediately result in widespread access to the drug for Australian 
women. All drugs licenced for use in Australia and made available 
for prescription by doctors must first pass through a rigorous 
process of approval by the TGA. The TGA acts to ensure that drugs 
used by the Australian public have been widely and appropriately 
tested, that they are safe, or at least that any side effects or contra-
indications are well known, and that they are effective. The TGA 
continues to monitor drugs after they have been approved for use in 
Australia, keeping a register of severe adverse effects, and it has the 
power to withdraw drugs from the Australian market. It is to the 
benefit of all of us that the TGA acts in this way. 
The TGA can generally only assess a drug when a drug company 
makes an application to manufacture and/or market that drug in 
Australia. At the time of writing this book, no such application  for 
mifepristone has been approved by the TGA, and it is believed that 
no such application has yet been lodged. Drug companies are not 
usually so reluctant to bring overseas drugs to Australian consumers, 
and the reasons why this hasn’t yet happened for RU486 are far 
from clear, although it seems certain that the political controversy 
surrounding the drug in Australia has played a major role.
However within the extensive legislation governing the role of the 
TGA there is provision for private doctors to apply to import and 
use particular drugs for their own patients, in certain serious medical 
conditions. This is called the Authorised Prescriber legislation. In 
late 2005 Dr Mike Carrette and I lodged an application under this 
legislation to be permitted to use mifepristone – RU486 - for the 
purpose of medical abortion in early pregnancy, in our own practices 
in Cairns. This was a complex process involving much paperwork 
but six months later (and two months after the overturning of the 
Harradine Amendment) this permission was granted to us. We 
were able to obtain a small supply of RU486 from New Zealand 
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colleagues and we have been using the drug in Cairns under the 
Authorised Prescriber guidelines for a year now.
In that time several other Australian doctors have made similar 
applications to the TGA but at the time of writing I am not aware of 
any others having been granted approval. Dr Carrette and I continue 
in the bizarre position of being the only medical practitioners in 
Australia able to use a drug that is widely prescribed and recognised 
overseas as the most appropriate choice for medical abortion.
I am hopeful that in the near future a drug company will lodge 
an application with the TGA – given the huge amount of overseas 
evidence in favour of the drug I believe it is likely that such an 
application would be granted. I very much look forward to the day 
when RU486 is simply a non-controversial option for women in this 
country,  one of many choices for reproductive health that currently 
include most forms of contraception, emergency contraception, 
surgical abortion and sterilisation. Meanwhile I have written this 
book to provide accurate information about RU486 and its actions 
to Australian women (and men), as well as to outline the history of 
the drug’s development, including its prolonged and unnecessary 
entanglement in the politics of the Howard government. 
SOME BASIC FACTS ABOUT RU 486
RU 486 was initially RU38486, and was  just one of many sample 
drugs in the French laboratories of the company  Roussel Uclaf 
-hence “RU”. It was first synthesised in April 1980, then lab-tested 
in France in 1981 before undergoing trials in patients (women 
volunteers) in France and Switzerland in 1981-82. Although it 
has since been formally named mifepristone – RU486 being the 
laboratory name only – and this is the name used by the medical 
profession, to the public it is still known and quickly recognised as 
RU486.
The drug is a synthetic steroid, meaning it has a chemical 
structure somewhat similar to the naturally-occurring sex hormones 
oestrogen and testosterone, but it is made in the laboratory, 
and does not occur in nature.  It acts by opposing the action of 
the naturally-occurring hormone progesterone. Progesterone is 
normally produced by one or other of a woman’s ovaries in the 
second half of the menstrual cycle. If a woman becomes pregnant 
progesterone production by the ovary increases and is supplemented 
by progesterone produced by the developing placenta. Progesterone 
is essential to the continuation of the pregnancy. When a pregnant 
women takes a single dose of RU486 the drug locks onto the 
chemical receptors in the lining of the uterus that normally bind 
with progesterone, thereby preventing natural progesterone from 
acting. This effectively ends the pregnancy because the placenta 
cannot develop.
RU486 has been found to have a number of potential uses in 
medicine (these are discussed further in Chapter 6). However its 
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best known and most widespread use at present is for the purpose of 
induced abortion. For this it is usually used together with another 
drug, misoprostol. Misoprostol is a synthetic form of prostaglandin. 
Like steroids, prostaglandins are substances some of which occur 
naturally in the human body, although misoprostol itself is made 
in laboratories. Misoprostol has a number of effects but the most 
important is to bring about contractions of the pregnant or recently 
pregnant uterus. This property has made it an effective treatment 
for post-partum haemorrhage – the heavy bleeding that can 
sometimes follow normal childbirth and threaten women’s lives. 
It also makes misoprostol useful in induced abortion as it brings 
about the expulsion of the contents of the uterus after mifepristone 
has ended the pregnancy. Misoprostol acts quickly – usually within 
four hours of being administered – and it does so generally with 
little blood loss. It is also very effective – the abortion process is 
usually complete after a single dose of misoprostol. The action of 
misoprostol on the uterus is increased by previously administering 
the mifepristone.
It needs to be made clear  that medical abortion using mifepristone/
misoprostol is not a ‘magic bullet’ that simply melts the pregnancy 
away. All the products of conception – which in the first trimester 
(the first twelve weeks of pregnancy) are mostly made up of placental 
tissue and membrane – need to be expelled from the woman’s body. 
This is a process that of necessity involves some bleeding and 
some pain – both of which are usually manageable by the woman 
concerned. Bleeding tailing off to a discharge takes a number of 
days to disappear completely following medical abortion. For most 
women this is no problem, women are used to vaginal bleeding, 
it’s scheduled to happen to them every month between the ages of 
12 and 50, and is normal for several weeks following childbirth. 
Medical abortion properly conducted also requires – usually –two 
or three visits to a doctor or clinic, and sometimes more. Surgical 
abortion properly conducted has similar requirements.
Various regimens are used in different countries but the principle 
of orally-administered mifepristone followed by orally or vaginally 
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administered misoprostol is common to all. When the abortion 
is performed before nine weeks of pregnancy (what is referred to 
medically as nine weeks’ gestation) this process can occur either 
in a clinic or hospital situation or in the woman’s own home. In 
the latter case the woman must initially be under medical care and 
must have access to emergency help in the event of a complication 
of the abortion, although complications are infrequent. Women 
experience early medical abortion much like a natural miscarriage. 
Crampy pain and vaginal bleeding are an intrinsic part of the 
abortion process as they are with miscarriage. Some tissue, which 
is visibly partly placenta and partly membranes, is passed, together 
with the fetus which is generally not recognisable as such. At six 
weeks of pregnancy the fetus (technically still called an embryo) is 
about 2 mm long, at seven weeks  5mm, and at eight weeks about 10 
mm (one centimetre) long.
Various studies have shown that with mifepristone-misoprostol 
regimens in recommended doses 95-99% of women will abort 
completely. The remainder will require uterine aspiration (or 
curettage, ‘D&C’) to complete the abortion, in a clinic or hospital 
situation. 
Mifepristone can also be used for later abortion, again in 
conjunction with misoprostol.  Medical abortions performed later 
than nine weeks are best performed in a hospital or clinic as there 
may be a need for strong analgesics (pain relief) and there is a 
greater risk of heavier bleeding than with early medical abortion. 
Nevertheless only a small percentage of late medical abortions 
actually incur these complications.
In the United Kingdom, early medical abortion using 
mifepristone/misoprostol has been available since 1991. It is now 
widely accessed by women – up to a third of early abortions in many 
centres in the UK are performed this way. Women have found the 
method highly acceptable – it is often described as less invasive, 
and allowing women to feel more in control, by those who have 
undergone the procedure. The Royal College of Obstetricians 
and Gynaecologists (RCOG), with headquarters in London, has 
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published detailed guidelines, based on the evidence of up-to-date 
research, about how the drugs should be used. Similar guidelines 
have been published by the American College of Obstetricians and 
Gynecologists (ACOG). In drawing up this information for doctors 
and for the women under their care, these Colleges have made clear 
their beliefs that RU486 is a safe, effective option for women who 
have made this choice of abortion for themselves.
All women considering termination of pregnancy should be 
provided with full information about all their options as well as 
available procedures and alternatives. Appropriate counselling and 
assessment by a doctor is vital. They should be offered other aspects 
of health care for women including follow-up contraception, Pap 
smear screening and screening for sexually transmitted infections, 
and they should be fully supported emotionally through the 
abortion process. It is important to make sure that the pregnancy is 
in the uterus and not an ectopic pregnancy e.g. in the fallopian tube, 
and that the abortion has caused all the products of conception to 
be expelled from the uterus. These considerations are as true of 
medical abortion as they are of surgical abortion. Surgical abortion 
is legal in all states of Australia under varying circumstances and 
is widely available but there are inequities of access to abortion 
services, and in some states although a Medicare rebate is payable 
abortions are generally performed in private clinics. Mifepristone 
and misoprostol are cheap to produce; misoprostol is currently 
available in Australia and is widely used in obstetric practice for 
conditions other than induced medical abortion (for example for 
women bleeding after normal vaginal births) although it is not 
licenced for these purposes. Numerous overseas studies have shown 
that the majority of women undergoing medical abortion have been 
“satisfied” or “very satisfied” with the procedure.
These are the basic facts. Why then if this safe option exists does 
medical abortion using RU486 continue to be, for all intents and 
purposes, unavailable to Australian women?
